Management of chemotherapy-related nausea and vomiting using a serotonin antagonist.
Patients receiving chemotherapy continue to experience nausea and vomiting despite recent strides to understand the physiology of these symptoms and despite current antiemetic therapies. Ondansetron, a serotonin antagonist, has shown to be a safe and effective drug in alleviating nausea and vomiting. This research-synthesis article provides summaries of eight clinical trials completed between 1988 and 1991. It includes a discussion of the pharmacodynamics and pharmacokinetics of ondansetron, suggestions for adverse events, and implications for nursing practice and future research.
Egan
A P
AP
Forbes Regional Health Center, Monroeville, PA.
Taggart
J R
JR
Bender
C M
CM
D000932:Antiemetics / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology / Q000627:therapeutic use*; D009325:Nausea / Q000139:chemically induced* / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy; D015399:Nursing Research; D009859:Oncology Nursing; D017294:Ondansetron; D012702:Serotonin Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced* / Q000188:drug therapy
D000932:Antiemetics; D000970:Antineoplastic Agents; D007093:Imidazoles; D012702:Serotonin Antagonists; D017294:Ondansetron